Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

e remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical studies have shown positive results; (ii) the Phase 2 data for NKTR-102 in breast cancer described in this press release remain subject to data audit confirmation procedures, and the final results may change materially and adversely after such review is completed; (iii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in breast cancer including but not limited to final progression-free survival and overall survival and therefore the complete results for the Phase 2 breast cancer trial may differ materially and adversely from these preliminary results; (iv) the timing or success of the commencement or end of clinical trials and commercial launch of new drugs may be delayed or unsuccessful due to commercial and funding considerations, regulatory delays, clinical trial design, slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (v) this early preliminary data from the NKTR-102 Phase 2 clinical study for breast cancer is not necessarily predictive of success in other cancer indications for which NKTR-102 is being studied (i.e. ovarian and colorectal cancers) or success in Phase 3 clinical development; (vi) the data package required and the timing for regulatory approval of a new drug application is very uncertain and difficult to predict due to broad regulatory discretion, changing standards of care, available approved therapies, the size of the completed clinical trials and the statistical significance of the results, the potential need for comparative clinical studies against approved therapies
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Calif. , Aug. 27, 2015 ... milestone in the commercial development of the company,s ... The Smart Oxygen device, being developed by ieCrowd,s ... to a patient,s changing demand for oxygen based ... the 510 (k) submission for the Smart Oxygen ...
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... Aug. 27, 2015   Women Grow , the fastest-growing professional ... partnering with the Cannabis World Congress & Business Exposition ... produce 15 business-focused educational sessions. CWCBExpo in LA will take ... Convention Center in Los Angeles, CA ... West Coast for the marijuana industry. The Women ...
Breaking Medicine Technology:Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... NKTR ) today announced positive results from ... study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian ... with prior Doxil® (pegylated liposomal doxorubicin or PLD) treatment ... criteria (response by tumor imaging) or Gynecologic Cancer InterGroup ...
... CHICAGO and SAN FRANCISCO, June 4, 2011 ... announced positive results from a Phase 2 clinical ... third-line treatment in patients with metastatic breast cancer ... Meeting (ASCO).  NKTR-102, a next-generation topoisomerase I inhibitor, ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 2NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 3NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 4NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 5NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 6NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 7NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 8NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 9
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... to have beneficial effects as sleep aids and calming remedies, which help to improve ... the result of a great deal of research in the field of regenerative medicine ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris Bustamante ... Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado ... its reach and impact through innovative technologies and strategies. , “I am very proud ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... support and protection against dribbled urine and sweat. "In order to prevent these ... , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a ...
(Date:8/29/2015)... Aliso Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Cut Pro X . Each preset contains 15 seconds of unique footage that users ... presets that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, ...
(Date:8/28/2015)... (PRWEB) , ... August 29, 2015 , ... Rio ... higher learning and the student experience as part of the EDUCAUSE - Next Generation ... Foundation . , This is the third Breakthrough Models Incubator hosted by ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... strikes a chord ... with frustrated women, SALT LAKE CITY, March 12 ... undertones., "I love the commercial because sometimes my husband remembers to ... make any,difference," says a customer service rep (who wishes to remain anonymous),at ...
... in U.S. may block brain receptor among some users ... weight-loss drug rimonabant has been associated with troubling psychiatric ... why. , A receptor in the brain called TRPV1, ... blocked by large doses of rimonabant (Acomplia), resulting in ...
... IVF Success, NEWBURGH, N.Y., March 12 ... Mount Sinai Hospital, is proud to introduce,premier fertility ... of,Reproductive Endocrinologist Jeffrey Klein, M.D. to its medical ... Westchester division of,Reproductive Medicine Associates (RMA) of New ...
... Institutets Board of Research confers the title honorary doctor ... have promoted activities carried out at the university. This ... conferred. The ceremony will take place on Friday 9 ... honorary doctors will receive their doctoral hats, diplomas and ...
... that restores a missing liver enzyme in test animals ... in humans, according to Duke University Medical Center researchers. ... disease type Ia (GSD-Ia), cant make an enzyme that ... that all cells use for energy. Without treatment, their ...
... Founders donating stock to establish corporate foundation; Community ... program helps care for the aging in Bay ... Caring.com is pleased to,announce its participation as the ... dedicated to engaging high-growth,companies in corporate citizenship and ...
Cached Medicine News:Health News:An Important Message to Anyone Taking Viagra ... From The Women Who Love You ... and Zoller Labs 2Health News:Possible Reason for Rimonabant's Side Effects Discovered 2Health News:Possible Reason for Rimonabant's Side Effects Discovered 3Health News:SLCH Brings Infertility Specialist to Region 2Health News:3 new honorary doctors at Karolinska Institutet 2Health News:Gene therapy could save kids from a lifetime of eating cornstarch 2Health News:Gene therapy could save kids from a lifetime of eating cornstarch 3Health News:Caring.com Joins Entrepreneurs Foundation as 200th Member 2
... YAG laser YC-1600 is a lightweight, compact, ... and clinical performance., ,Key Features, , ... Model ,Further weight reduction has been made ... office.,, Aiming Beam Rotation ,(360 degrees ...
... system, developed by Given Imaging of Israel, is ... a grape. Weighing in at only four grams, ... LED lights, battery and radio transmitter coated by ... digestive enzymes. Internal gastric images are transmitted to ...
... Bravo pH Monitoring System is ... is done. Bravo allows patients ... and activities during pH testing. ... the added convenience for patients ...
... TMR technology is an effective ... vessels with poor targets. Because ... surgical suites, the CO2 Heart ... to make timely operative decisions ...
Medicine Products: